



Estimating the economic burden of osteoporotic fractures in a multinational study: a real-world data perspective

A. Moayyeri¹ · J. Warden¹ · S. Han² · H.S. Suh^{3,4} · R. Pinedo-Villanueva⁵ · N.C. Harvey^{6,7} · J.R. Curtis⁸ · S. Silverman⁹ · J.K. Multani¹⁰ · E.J. Yeh¹¹ 

Received: 21 February 2023 / Accepted: 21 August 2023
© The Author(s) 2023

Abstract

Summary Fracture-related costs vary by country. A standardized methodology and presentations were proposed to fairly assess the economic burden of osteoporotic fracture. Results indicated substantial costs of osteoporotic fractures for pharmacy, hospitalization, emergency care, and outpatient visits in women aged ≥ 50 years in Australia, Germany, South Korea, Spain, and the USA.

Purpose The objective of this multinational, retrospective matched cohort study was to use a standardized methodology across different healthcare systems to estimate the burden of osteoporotic fracture (OF) in women aged ≥ 50 years in Australia, Germany, South Korea, Spain, and the USA.

Methods Within each country, healthcare resource utilization and direct costs of care were compared between patients with newly identified OF and a propensity score-matched cohort without OF during follow-up periods of up to 5 years.

Results Across all five countries, the OF cohort had significantly higher rates and length of inpatient admissions compared with the non-OF cohort. In each country, the adjusted total costs of care ratio between OF and non-OF cohorts were significant. The adjusted cost ratios for pharmacy, inpatient care, emergency care, and outpatient visits were similarly higher in the OF cohort across countries.

Conclusion The current study demonstrates the substantial economic burden of OF across different countries when compared with matched non-OF patients. The findings would assist stakeholders and policymakers in developing appropriate health policies.

Keywords Fractures · Healthcare resource utilization · Osteoporosis · Real-world evidence · Research methods

✉ E.J. Yeh
eyeh01@amgen.com

¹ UCB Pharma, Slough, UK

² Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA

³ College of Pharmacy, Kyung Hee University, Seoul, South Korea

⁴ Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, South Korea

⁵ Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, NIHR Oxford Biomedical Research Centre, University of Oxford, Windmill Road, Oxford OX3 7HE, UK

⁶ MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, UK

⁷ NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital NHS Foundation Trust, Southampton, UK

⁸ Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA

⁹ Cedars-Sinai Medical Center and School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

¹⁰ IQVIA, Falls Church, VA, USA

¹¹ Amgen Inc., Thousand Oaks, CA, USA

Introduction

Osteoporotic fractures (OF) are a major global public health concern, associated with significant clinical, economic, and societal burden worldwide, with various healthcare and treatment approaches among countries [1, 2]. An important component of the direct economic burden of OF is the direct cost of care, which includes inpatient/outpatient care, treatments, use of rehabilitation and equipment, nursing facilities, and other medical and pharmacy services. A retrospective US study of over 300,000 OF patients estimated an average of \$34,855 in annual all-cause healthcare costs per patient [1]. The OF-related costs in the Australian healthcare system in 2012 were estimated as \$1.6 billion in direct costs [3]. The OF-related direct costs in six European countries (France, Germany, Italy, Spain, Sweden, and the UK) amounted to €37.5 billion in 2017 [4]. In South Korea, the OF-related direct cost to the national health system increased from \$549 million in 2008 to \$722 million in 2011 [5]. The variation in cost estimates among countries could be attributed to differences in country-specific healthcare and payer systems, socioeconomic determinants of health, geopolitical factors, national wealth, and health status of the population [6–8], as well as differences across studies in the fracture sites of interest, data availability, and methodology. These differences lead to challenges in interpreting and comparing economic evaluation involving healthcare resource utilization (HCRU) and costs of care across studies. Hence, to facilitate appropriate interpretations and fair comparisons of OF-related HCRU and cost data across studies, it is critical to account for country-specific differences in study design and participant selection, along with national differences in healthcare systems and costs. Most publications documenting the economic burden of OF are based on data from individual countries; therefore, there is a shortage of directly comparable multi-country real-world evidence. Addressing the inconsistencies due to country-specific and methodological variations would not only highlight the magnitude of economic burden of OF, but also aid appropriate economic evaluation and healthcare resource allocation and prioritization.

Here, to overcome several of these shortcomings, we propose a standardized methodological approach using real-world datasets for economic evaluation of the burden of OF compared with its non-OF pair across multiple countries. We aimed to illustrate the advantages of using a standardized methodology by presenting HCRU and cost data from Australia, Germany, South Korea, Spain, and the USA to provide global insights from patients across North America, Europe, Australia, and Asia. This study may also be used as a reference point for further in-depth country-specific publications.

Materials and methods

Overview of study design

This multinational, retrospective matched cohort study assessed the direct economic burden of OF from 2013 to 2020 in women aged ≥ 50 years from Australia, Germany, South Korea, Spain, and the USA. Within each country, HCRU and cost data derived from patients with newly identified OF (OF cohort) and matched patients without OF (non-OF cohort) were compared. The index date for the OF cohort was defined as the date of the first incident OF within each 6-month calendar period during the index period, and the same index date was then assigned as the index date for the non-OF cohort. The pre-index period for each patient corresponded to at least 18 months preceding the index date, and baseline information, such as comorbidities, medication use, pre-fracture HCRU, and costs of care, was collected. The follow-up period for each patient was defined as the period extending from the index date to the end of follow-up (defined as the earliest of the end of the study period, death (if available), fracture event (applicable to non-OF cohort), or lost to follow-up). Only fractures within each 6-month matching period (called “panel” or 6-month index period) were used as the index fracture for the OF cohort. If a fracture occurred after the 6-month matching period of up to 5 years, it was considered either a recurrent event for the OF cohort or an event to be censored for the non-OF cohort. The follow-up period ranged from a minimum of 1 month to 5 years from the index date (Fig. 1).

Study population

The OF cohort was defined as patients meeting all the following criteria: (i) women aged ≥ 50 years who experienced an incident OF (i.e., low or no trauma fracture; Supplementary Table 1) during each 6-month index period/panel, (ii) with continuous enrollment in the database for ≥ 18 months prior to and at ≥ 1 month after index date, and (iii) without an OF in the 18-month pre-index period. Claims with diagnosis codes for fractures after the 18-month fracture-free period were treated as incident fractures. The following hierarchical approach was used to categorize the type of index fracture for a patient with two different OFs on the same day and gave precedence to fractures in the following order: hip, vertebral, pelvis, tibia-fibula, radius-ulna, humerus, ribs, clavicle, and scapula. Diagnosis codes for trauma (Supplementary Table 2) were used to exclude patients with a traumatic fracture during each 6-month index period. To minimize the potential inclusion of fractures related to traumatic accidents/events but not recorded as traumatic, women with three or more types of fractures on the index date were




Fig. 1 Study design. The study periods for the Germany and US studies reflect the latest available data at the time of the study and are different from dates shown above. OF, osteoporotic fracture. *Study period for Germany: July 1, 2013, to December 31, 2018; for the USA: July 1, 2013, to December 31, 2020. **Subject identifica-

tion period for Germany: July 1, 2014, to November 30, 2020; for the USA: January 1, 2015, to November 30, 2020. †There were 12 panels during the subject identification period; each panel had 6-month panel to identify subjects, except the last panel which had a 5-month period to allow a 1-month follow-up period

excluded from the selection process. The non-OF cohort was defined as patients meeting the following criteria: (i) women aged ≥ 50 years, (ii) with continuous enrollment in the database for ≥ 18 months prior to and ≥ 1 month after the assigned index date, and (iii) with no record of OF during the pre-index period. For both cohorts, women with a record of participation in a clinical trial pertaining to osteoporotic treatment during the pre-index period, with a diagnosis of cancer (except non-melanoma skin cancer), Paget's disease of the bone, osteitis deformans, osteopathies, or metabolic bone diseases (e.g., osteomalacia, hyperparathyroidism, and osteogenesis imperfecta) during the study period were excluded to minimize the potential impact of these conditions on OF-related outcomes.

Matching

The subject identification period in each country was divided into 6-month index periods ("panels"), except the last 5-month panel, to identify eligible women with OF and a pool of non-OF women eligible for matching. Supplementary Figure 1 depicts the overall processes. For each 6-month panel, non-OF women were first age-matched to OF women using their birth month and year (± 12 months). The matched non-OF women were assigned a random date during the 6-month panel as their "temporary" index date. After identifying an age-matched group of non-OF women for all OF women in each 6-month panel, propensity scores were generated for OF and non-OF women using multivariate logistic regression with the following baseline characteristics: geographic region, race/ethnicity (if available in

the country dataset), pre-index glucocorticoid use, pre-index hormone replacement therapy use, pre-index anti-osteoporosis drug use, residence (i.e., living at home or in an institution), Charlson Comorbidity Index (CCI), selected comorbidities (i.e., osteoporosis, cardiac disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), asthma, diabetes, depression, and anxiety), and number of pre-index hospitalizations [9–11]. For each OF woman, up to three age-matched non-OF women with the smallest difference in propensity score were identified. After the identification of matches for all OF women, the index date of OF women was assigned to their non-OF matches, and all were added to the analysis set. The same matching process was applied to the second 6-month panel and so forth. In case of a non-OF woman being matched to multiple OF patients, she was only considered matched to the "earliest index date" woman. If a non-OF woman had a fracture during follow-up, she was censored on the date of her fracture, and post-fracture data were not included in any analyses after her fracture date nor assigned to the OF cohort post-fracture (i.e., was not reassigned to the OF cohort).

Data sources

Data were extracted from electronic medical records (EMR) or administrative claims databases or surveys. The countries assessed were selected as examples of four continents, and data sources were selected for diversity in terms of data types and feasibility to generate high-quality real-world evidence. A summary of data source characteristics across the

countries is presented in Table 1. These data sources are briefly described in the Supplementary material.

Outcome measures

Direct all-cause HCRU included any resource/service directly available or identifiable from the study data source in each country, including hospitalizations (defined as at least one overnight stay in the hospital), emergency room/accident and emergency (ER/A&E) visits (defined as hospital ER visit without an overnight stay or visit to a stand-alone urgent care facility), physician visits (defined as a visit to primary care or a specialist or an outpatient clinic),

nurse visits, home visits (by a nurse or a physician), diagnostic and/or procedures, and prescriptions, use of physical therapy (physiotherapy) and/or occupational therapy, and ambulance use were reported if available in the data sources. Reported costs of each resource/service were used to calculate sums by service type (i.e., medical (sum of medical inpatient, outpatient, and ER), medical inpatient (excluding ER), outpatient (excluding ER), ER, and pharmacy). Total direct all-cause healthcare costs were the sum of medical and pharmacy costs. For South Korea, pharmacy costs were summed with medical costs as pharmacy costs could not be reported separately in the data. All costs were adjusted using a country-specific consumer price index and presented in

Table 1 Data source characteristics and components across countries

Country	Australia	Germany	South Korea ^a	Spain ^a	USA ^a
Main database	45 and Up Study linked to administrative claims	InGef	NHIS	SIDIAP linked to hospital admissions data	PharMetrics Plus
Years accessed ^b	July 2011–Dec 2018	July 2013–Dec 2018	July 2011–Dec 2018	July 2011–Dec 2018	July 2013–Dec 2020
Study population (<i>N</i>)	18,730	45,542	182,051	100,522	764,126
Type of database					
EMR				Main	
Claims	Linked	Main	Main		Main
Survey	Main				
Sampling approach of the database(s)	Prospective survey cohort study linked to regional/national administrative claims	Individuals insured in 60 SHI	National administrative claims of inpatient and outpatient visits	Primary care data linked to regional hospital admissions data	Predominantly commercially managed/self-insured health plans
Coverage					
Regional	√	√		√	
National			√		√
Data components					
Mortality	√	√	√	√	N/A
Prescription information ^c	√	√	√	√	√
Hospitalization claims	√	√	√	√	√
Primary care	√	√	√	√	√
ER claims	√	√	√	√	√
Home visits	√	√	√	√	√
Use of supportive equipment	√	√	√	N/A	√
Rehabilitation facility use	√	N/A	√	N/A	√
Nursing home use	√	N/A	√	N/A	√
Falls	√	N/A	√	√	√

Legend: √: available; N/A: not available

^aRace/ethnicity not available

^bThe latest available data at the time of the study

^cFor South Korea, pharmacy costs were summed with medical costs due to data limitations

EMR electronic medical records, ER emergency room, NHIS National Health Insurance Service, SHI statutory health insurances, SIDIAP Information System for Research in Primary Care

2018 USD for all countries except the USA (2021 USD). If there were multiple data on baseline demographic characteristics during the pre-index period, the information reported closest to the index date was chosen.

Statistical analysis

Descriptive statistics were used to describe patient characteristics and outcomes in the OF and non-OF cohorts within each country. The proportion of women with at least one utilization for each resource type (e.g., ≥ 1 hospitalization) during the post-index follow-up period was reported. Post-index all-cause HCRU and associated costs are presented as a rate on a per person-year basis as the frequency of utilizations or total costs divided by the total follow-up time (in years) contributed by each woman. The adjusted rate ratio of OF (numerator) compared with non-OF (denominator) cohorts in all-cause HCRU person-year rates was assessed using negative binomial regression models with log-link function, adjusted for baseline characteristics with a standardized difference $\geq 10\%$ after matching. The adjusted rate ratio of OF (numerator) compared with non-OF (denominator) cohorts in all-cause costs was assessed using generalized linear models with gamma distribution and log-link function, adjusted for baseline characteristics with a standardized difference $\geq 10\%$ after matching and residence at index date (Supplementary Table 3). The gamma distribution with the log-link was chosen considering the skewed distribution of costs. The matching group was included as a random intercept to account for the matching design, and person-years was included as an offset (applying the logarithm function) to account for differences in follow-up time for the HCRU and cost rate ratio models. These regression models were chosen based on the distribution of their dependent variables and have been used in real-world data analyses [12, 13]. Sub-analyses included post-index HCRU and cost outcomes by year since index in 1-year intervals, index fracture type, and imminent risk groups of fracture. Further interpretation and results of the subgroup analysis will follow in future country-specific publications.

Results

The total number of patients meeting the study eligibility criteria by country is shown in Supplementary Table 4. After matching, the following number of OF patients and matched controls, respectively, was identified: Australia, 4809 and 13,921; Germany, 11,452 and 34,090; South Korea, 47,238

and 134,813; Spain, 25,214 and 75,308; and the USA, 193,262 and 570,856 (Supplementary Table 5).

Baseline demographics and clinical characteristics

Most patients' baseline demographic and clinical characteristics between OF and matched non-OF cohorts within each country were balanced, except for the number of pre-index hospitalizations for Germany and geographic region, cardiac disease, and cerebrovascular disease for Australia (standardized difference of means $\geq 10\%$; Supplementary Table 3). Key baseline characteristics are presented by country in Table 2. The mean (SD) age of OF patients ranged from 63.3 (9.2) years in the USA to 76.6 (10.1) years in Germany. For controls, the mean age ranged from 63.1 (9.2) years in the USA to 76.7 (10.0) years in Germany. The average follow-up time (months) for the OF cohort ranged from 18.1 in the USA to 34.6 in South Korea. For the controls, the range in follow-up time was from 19.1 in the USA to 35 in South Korea. During the pre-index period, percentages of osteoporosis diagnosis in the OF cohort ranged from 3.9% in Spain to 21.6% in Australia. Percentages of the OF patients with a record of anti-osteoporosis therapy ranged from 5.9% in Germany to 19.8% in South Korea. In the OF cohort, the top two fracture types at index date were radius-ulna (29.2%) and hip (26.2%) for Australia, hip (32.7%) and vertebral (18.7%) for Germany, vertebral (42.4%) and radius-ulna (30.4%) for South Korea, radius-ulna (24.0%) and vertebral (18.1%) for Spain, and radius-ulna (31.4%) and tibia-fibula (17.4%) for USA (Table 3).

Healthcare resource utilization

The adjusted rate ratios of HCRU (OF and non-OF) by country and service type are presented in Table 4. In each country, OF cohorts had significantly higher rates than non-OF cohorts in all types of HCRU, except for outpatient specialist visits in Germany. Specifically, the OF cohort had significantly higher rates of inpatient admissions (2.1 in Australia to 3.9 in the USA), nights stayed at the hospital (1.71 in Germany to 11.52 in the USA), all-type outpatient visits (1.19 in Australia to 2.0 in the USA), ER visits (1.04 in Germany to 3.19 in the USA), home visits (1.27 in Germany to 4.74 in the USA), and prescriptions than the non-OF cohort, where available. The adjusted rate ratios for nights stayed at the hospital, ER visits, and home visits for the OF cohort were higher than those for the non-OF cohort among all countries, most notably in the USA. The adjusted rate ratio for prescriptions ranged from 1.04 in Australia to 1.45 in South Korea. HCRU per 100 person-years during the follow-up period between OF

Table 2 Baseline demographic and clinical characteristics^a

Country	Australia		Germany		South Korea		Spain		USA	
	OF	Non-OF	OF	Non-OF	OF	Non-OF	OF	Non-OF	OF	Non-OF
<i>N</i>	4809	13,921	11,452	34,090	47,238	134,813	25,214	75,308	193,262	570,864
Age at index, years, mean (SD)	75.4 (11.6)	75.3 (11.7)	76.6 (10.1)	76.7 (10.0)	71.2 (11.1)	70.8 (11.1)	73.3 (11.9)	73.2 (11.9)	63.3 (9.2)	63.1 (9.2)
Follow-up, months, median (Q1–Q3)	31 (15.0–49.0)	33 (16.0–51.0)	26.5 (13.1–40.2)	24.6 (12.3–38.4)	34.6 (16.9–52.6)	35.0 (17.4–52.8)	34.0 (16.0–52.0)	32.0 (16.0–50.0)	18.1 (7.9–34.2)	19.1 (8.6–35.6)
Pre-index treatment use, <i>n</i> (%)										
Glucocorticoids	545 (11.3)	1577 (11.3)	1638 (14.3)	4232 (12.4)	27,078 (57.3)	74,686 (55.4)	1273 (4.8)	3561 (4.5)	70,577 (36.5)	202,620 (35.5)
Hormone replacement therapy	669 (13.9)	2185 (15.7)	1143 (9.9)	3146 (9.2)	2396 (5.1)	5794 (4.3)	15 (0.1)	20 (0.0)	12,065 (6.2)	31,721 (5.6)
Anti-osteoporosis therapy	309 (6.4)	1116 (8.0)	680 (5.9)	1940 (5.7)	9368 (19.8)	24,077 (17.9)	2687 (10.7)	7826 (10.4)	13,798 (7.1)	40,545 (7.1)
CCI, <i>n</i> (%)										
0–1	4464 (92.8)	13,025 (93.6)	6342 (55.4)	18,424 (54.0)	26,936 (57.0)	78,835 (58.5)	18,676 (74.1)	54,234 (72.0)	158,250 (81.9)	473,171 (82.9)
2–3	303 (6.3)	790 (5.7)	4075 (35.6)	12,141 (35.6)	14,474 (30.6)	40,381 (30.0)	5503 (21.8)	17,722 (23.5)	26,882 (13.9)	75,308 (13.2)
> 3	42 (0.9)	106 (0.8)	1035 (9.0)	3525 (10.3)	5828 (12.3)	15,597 (11.6)	1035 (4.1)	3352 (4.5)	8130 (4.2)	22,385 (3.9)
Osteoporosis diagnosis, <i>n</i> (%)	1039 (21.6)	3182 (22.9)	521 (4.6)	1429 (4.2)	7067 (15.0)	17,921 (13.3)	989 (3.9)	2902 (3.9)	21,922 (11.3)	64,184 (11.2)
Cardiac disease, <i>n</i> (%)	1139 (23.7)	3868 (27.8)	9354 (81.6)	29,064 (85.2)	27,905 (59.1)	79,083 (58.7)	4882 (18.5)	14,021 (17.8)	101,912 (52.7)	306,781 (53.7)
Cerebrovascular disease, <i>n</i> (%)	269 (5.6)	876 (6.3)	2623 (22.9)	8280 (24.2)	8511 (18.0)	24,071 (17.9)	650 (2.5)	2061 (2.6)	14,840 (7.7)	43,497 (7.6)
Diabetes, <i>n</i> (%)	692 (12.5)	2388 (14.8)	1030 (8.9)	2871 (8.4)	13,881 (29.4)	37,663 (27.9)	1068 (4.1)	3265 (4.2)	31,780 (16.4)	91,445 (16.0)
Fall, <i>n</i> (%)	468 (9.7)	783 (5.6)	NA	NA	53 (0.1)	68 (0.1)	1870 (7.4)	1460 (1.9)	14,929 (7.7)	17,126 (3.0)

CCI Charlson Comorbidity Index, NA not available, OF osteoporotic fracture, Q1 25th percentile, Q3 75th percentile, SD standard deviation

^aMeasured during the 18-month pre-index period, unless otherwise specified

Table 3 Fracture type on the index date among OF women

Country	Australia	Germany	South Korea	Spain	USA
<i>N</i>	4809	11,452	47,238	25,214	193,262
Fracture type, <i>n</i> (%)					
Hip	1262 (26.2)	3743 (32.7)	4006 (8.5)	3163 (12.5)	15,319 (7.9)
Pelvis	444 (9.2)	785 (6.9)	1033 (2.2)	1513 (6.0)	7261 (3.8)
Femur	154 (3.2)	771 (6.7)	888 (1.9)	1459 (5.8)	3295 (1.7)
Vertebral	284 (5.9)	2145 (18.7)	20,028 (42.4)	4557 (18.1)	23,093 (11.9)
Scapula	40 (0.8)	76 (0.7)	49 (0.1)	77 (0.3)	1154 (0.6)
Humerus	642 (13.3)	1033 (9.0)	1440 (3.1)	3713 (14.7)	23,156 (12.0)
Radius-ulna	1403 (29.2)	1277 (11.2)	14,375 (30.4)	6045 (24.0)	60,737 (31.4)
Tibia-fibula	267 (5.6)	768 (6.7)	1829 (3.9)	2640 (10.5)	33,600 (17.4)
Clavicle-rib	313 (6.5)	854 (7.5)	3590 (7.6)	2047 (8.1)	25,647 (13.3)

OF osteoporotic fracture

and non-OF cohorts for each country is presented in Supplementary Table 5.

Direct costs of care

The adjusted rate ratios of costs of care (OF and non-OF) by country and service type are presented in Table 5. In each country, OF cohorts had significantly higher rates of cost of care than non-OF cohorts for all cost types, except for ER (1.04; 95% CI 0.99–1.08) in Australia. The adjusted rate ratio of total costs of care was significantly higher in the OF cohort compared with the non-OF cohort, ranging from 1.38 (95% CI 1.35–1.41) in Germany to 3.11 (95% CI 3.09–3.13) in the USA. The highest adjusted rate ratio of total medical cost was observed for the USA (3.69; 95% CI 3.67–3.72) and the lowest for Germany (1.42; 95% CI 1.38–1.46). Mean costs during the follow-up period between OF and non-OF cohorts for each country are presented as per 100 person-years in Supplementary Table 6.

Discussion

The current study explored the economic burden of OF across multiple countries compared to non-OF women that reflected care in the contemporary landscape in different parts of the world. The main study results suggest that OF patients tended to use more healthcare resources and incur higher costs than non-OF patients. These differences illustrate the impact of OF on direct economic burden when a standardized methodology was used, despite variance in available data sources (e.g., some components of HCRU or costs were not captured in data sources) across countries.

The findings of the significant impact of OF on direct economic burden are aligned with most findings reported in the literature [2, 4]. In a US matched case-control study, Tran et al. reported low osteoporosis diagnosis (4–10.6%)

and treatment rates (8.2–17.6%) prior to fracture in commercially insured female patients [1, 14]. In 2017, the treatment gap among women in EU6 was 73%, with the highest rate observed for Germany (78%) [4]. The highest radius-ulna fracture rate observed in the current study for the USA (31.4%) may be attributable to a younger study population compared with the other countries (mean age = 63 vs. 71–77 years). In a 2017 US claims-based analysis among commercial and Medicare patients, the radius-ulna (19.5%) was the second most common index fracture type after the spine (21.9%) [1]. The top three fracture types observed for Spain (radius-ulna, vertebral, and humerus) are somewhat consistent with the epidemiologic literature, although hip fractures are known to be the most frequent followed by forearm and vertebral fractures [15]. In the current study, propensity score matching with 6-month periods/panels allowed for the adjustment of several potential confounders, which is advantageous over the direct matching technique used by Tran et al. Nonetheless, the authors were able to demonstrate significantly higher adjusted excess costs for OF vs. non-OF cohorts over each follow-up period [14].

This study used a standardized methodology for all five countries to minimize methodological variance when data were compared across countries. The advantages of the current methodology included (i) use of propensity score matching in each of the 6-month panels to identify non-OF cohorts, with consideration of potential observed variables and to ensure matched patients were from similar time frames, reducing any difference that may have been caused by change in care practice over time, (ii) use of the person-year approach to account for variable follow-up time, (iii) use of multivariate regression to adjust for additional variables including those imbalanced variables after propensity score matching, and (iv) use of the ratio approach to present results, which theoretically cancel out unobserved variables (such as economic ramifications and regional variance mentioned in “Introduction”) because these variables are likely

Table 4 Adjusted rate ratios of healthcare resource utilization between OF and non-OF by country and service type

Country	Australia		Germany		South Korea		Spain		USA	
	OF	Non-OF	OF	Non-OF	OF	Non-OF	OF	Non-OF	OF	Non-OF
Number of patients	4809	13,921	11,452	34,090	47,238	134,813	25,214	75,308	193,262	570,864
Inpatient admissions ^a	2.10 (1.98–2.23)		1.16 (1.13–1.18)		3.18 (3.10–3.27)		2.13 (2.08–2.19)		3.90 (3.84–3.95)	
Nights stayed at hospital at hospital rate	4.11 (3.76–4.50)		1.71 (1.64–1.78)		4.70 (4.54–4.85)		4.04 (3.85–4.24)		11.52 (11.23–11.82)	
All-type outpatient visit rate ^b	1.19 (1.16–1.22)		NA		NA		1.27 (1.26–1.29)		2.00 (1.99–2.01)	
Outpatient primary care visit rate ^c	1.10 (1.07–1.13)		1.11 (1.08–1.14)		NA		1.26 (1.25–1.28)		1.32 (1.31–1.33)	
Outpatient specialist visit rate ^d	1.21 (1.17–1.25)		1.02 (1.00–1.04)		1.81 (1.78–1.85)		1.08 (1.05–1.12)		2.29 (2.27–2.30)	
Other outpatient service rate ^e	1.20 (1.16–1.24)		1.21 (1.20–1.23)		1.02 (1.01–1.03)		1.28 (1.27–1.30)		1.93 (1.92–1.94)	
ER visit rate ^f	1.21 (1.14–1.29)		1.04 (1.02–1.06)		1.82 (1.77–1.87)		NA		3.19 (3.17–3.22)	
Home visit rate ^g	1.29 (1.22–1.37)		1.27 (1.24–1.30)		NA		1.91 (1.85–1.98)		4.74 (4.68–4.80)	
Prescription rate ^h	1.04 (1.01–1.07)		NA		1.45 (1.44–1.46)		1.07 (1.06–1.08)		1.19 (1.18–1.20)	

Parenthesis indicates 95% confidence interval

ER emergency room, NA not available, OF osteoporotic fracture

^aAt least one overnight stay in the hospital as an inpatient

^bAll outpatient types combined: primary care, specialist, and others

^cOutpatient primary care visit: office/clinic visit general physician or primary care physician

^dOutpatient specialist visit: office/clinic visit to specialist (e.g., rheumatologist, orthopedist)

^eOther outpatient services: clinic/facility visit for lab/radiology, skilled nursing facility, physical/occupational rehabilitation services and any other ancillary services

^fEmergency room visit: care received in the emergency department

^gHome visit information is based on home visits or domiciliary care visits

^hPrescription is based on all filled pharmacy prescription claims including refill prescriptions

Table 5 Adjusted rate ratio of healthcare costs between OF and non-OF by country and service type

Country	USA		Australia		Germany		Spain		South Korea	
	OF	Non-OF	OF	Non-OF	OF	Non-OF	OF	Non-OF	OF	Non-OF
<i>N</i>	193,262	570,864	4809	13,921	11,452	34,090	25,214	75,308	47,238	134,813
Total costs of care ^a	3.11 (3.09–3.13)	1.83 (1.77–1.90)	1.83 (1.77–1.90)	1.38 (1.35–1.41)	1.66 (1.64–1.69)	2.87 (2.80–2.94)				
Total medical costs ^b	3.69 (3.67–3.72)	2.00 (1.93–2.08)	2.00 (1.93–2.08)	1.42 (1.38–1.46)	1.85 (1.82–1.88)	NA				
Total pharmacy costs ^c	1.13 (1.12–1.14)	1.11 (1.07–1.15)	1.11 (1.07–1.15)	1.27 (1.24–1.30)	1.26 (1.25–1.28)	NA				
Total medical inpatient costs ^d	2.17 (2.14–2.20)	1.59 (1.52–1.67)	1.59 (1.52–1.67)	1.61 (1.52–1.70)	NA	1.99 (1.93–2.05)				
Total ER costs ^e	1.74 (1.72–1.76)	1.04 (0.99–1.08)	1.04 (0.99–1.08)	NA	NA	1.54 (1.38–1.72)				
Total outpatient costs ^f	2.52 (2.50–2.53)	1.23 (1.20–1.26)	1.23 (1.20–1.26)	1.04 (1.02–1.06)	1.31 (1.26–1.33)	1.28 (1.26–1.29)				

Parenthesis indicates 95% confidence interval

ER emergency room, NA not available, OF osteoporotic fracture

^aTotal medical and total pharmacy costs are considered

^bTotal medical cost: the sum of total inpatient, outpatient, and ER

^cTotal pharmacy cost: total cost of filled prescriptions

^dTotal medical inpatient cost: total cost of services from all inpatient claims

^eEmergency room cost: total cost of services from all ER claims

^fTotal medical outpatient cost: total cost of services from all outpatient claims (excluding ER, and including visits, diagnostics, and procedures)

equal in both OF (in denominator) and non-OF (in numerator) cohorts within the same country. All of these were designed to minimize potential biases when differences in all-cause HCRU and costs of care between the OF and non-OF cohorts were assessed. To the best of our knowledge, this adjusted rate ratio approach was the first to be used in published healthcare research in a multi-country analysis in the therapeutic area of bone health.

Overall, the adjusted total cost of care was significantly higher in the OF cohort than in the non-OF cohort in each country, ranging from a ratio of 1.38 in Germany (95% CI 1.35–1.41) to 3.11 in the USA (95% CI 3.09–3.13). The adjusted cost ratios for pharmacy, medical inpatient, ER, and outpatient visits were similarly higher in the OF cohort across the participating countries.

Interpretation of country data should be taken with caution, as the demographic and clinical makeup of country-specific data varied. For example, the US cohorts were about 10 years younger on average than those in other countries, and the average length of follow-up time was shorter. This can be partially explained by the features of PharMetrics® Plus database, where (a) data were primarily from working-age populations based on commercial health plans and self-insured employer groups and (b) plan switches may be common because of the nature of annual subscriptions that led to shorter follow-up time. Changes in insurance coverage (most applicable to the USA) and covered populations in the data sources may also have an impact on HCRU or its subtypes (or components). In Spain, SIDIAP data have high specificity but low sensitivity with respect to reporting of OF in primary care alone compared with cohort studies or hospital discharge data because of the under-reporting of OF in primary care records [16]. However, our linkage to CMBD regional hospital data allowed for an increased sensitivity of OF. The total direct cost of care is underestimated in Spain, Germany, and South Korea due to the unavailability of ER costs for Germany and Spain and the combined medical and pharmacy costs for South Korea. Additionally, all-cause costs of care presented in this study may be influenced by comorbidities that may be related to OF, despite using non-OF cohorts as controls. Future studies may consider an assessment of OF-related costs of care.

Although direct comparisons between countries should be made with caution, a clear trend of increased economic burden in OF compared to non-OF patients, especially presented as rate ratios, was observed across countries. In the current study, the highest relative effect of OF compared with non-OF among HCRU settings was observed for nights stayed at hospital across all countries. Among the cost categories, the highest relative effect of OF compared with non-OF was observed for total medical costs. When HCRU is presented in person-year rates and cost data are presented in absolute numbers, it is difficult to ascertain such relationships across

countries with varying healthcare or payer systems, expenditure, and gross domestic product (GDP).

From a clinical perspective, the observations necessitate the need for greater awareness of OF impact among patients and healthcare providers, particularly the need for prevention (which is evidenced by low rates of osteoporosis diagnosis and anti-osteoporosis therapy in the pre-index period) and post-care programs (which showed various levels of HCRU). Tran et al. demonstrated that the cost of fracture in the first year after fracture was higher than that in subsequent years [14].

In addition to generating valuable real-world evidence, the current study is uniquely positioned in terms of methodology, and its uniform application across data sources provides a high level of generalizability of the findings due to the similarity in trends observed, as presented in rate ratios, across countries. The current work presents a more robust approach to assess the direct economic burden of OF utilizing the rate ratio approach to demonstrate study results. Incentives to employ resources for osteoporosis or OF-related care that are country-specific, or that are relevant to all disease states, could have an impact on HCRU (as reflected in HCRU for non-OF cohorts). It is challenging to compare HCRU across countries using presentations that employ various HCRU frequency levels. Additionally, many of these country-specific variations may be eliminated if the differences between OF patients and similar non-OF patients from the same country are considered for economic burden evaluations. A standardized methodology to present the economic burden of OF across countries can address the current gaps in the literature, which can help stakeholders and policymakers tailor preventive fracture and post-fracture treatment programs.

Limitations

This study has inherent limitations with respect to its retrospective cohort design. Eligible female patients were required to be enrolled for a minimum of 18 months for the study as fracture-free during the pre-index period to ensure that the index fracture was an incident fracture, which may exclude some women who changed health insurance (applicable for the USA) or health practice or did not capture previous fractures incurred prior to the pre-index period. Furthermore, the less granular M80 codes (Supplementary Table 1) by themselves do not discriminate between past or new fractures and may be vague as to the specific fracture sites (e.g., M80.9). In our consideration of various clinical practices and adaptations of the ICD coding system across countries (e.g., M80.5 and M80.9 are not valid diagnosis codes in the US ICD-10-CM coding system and indeed were limited to the Korean study population in which these codes identified less than 0.3% of the OF group) and attempt

to capture all possible incident fractures, we assumed that claims with ICD codes for prevalent fractures (e.g., M80.5 and M80.9) after the 18-month fracture-free period would be treated as incident fractures for the purpose of this study. The analysis does not include the data of patients who were moved to care homes/assisted living, so related HCRU was not reported, and the true costs of care would be underestimated. South Korean medical costs may need to be interpreted carefully as they could not be separated from pharmacy costs. The claims data are gathered for billing purposes rather than research, and hence, several clinical risk factors for OF were unavailable (e.g., bone density). Specific to the Australian dataset, “use of supportive equipment” was not reported, because this was neither collected nor reported in the administrative government datasets. Specialist visits in a hospital setting could be under-reported. This is not quantifiable as outpatient specialist care within a hospital is not picked up by the Australian MBS and PBS or specifically within NSW databases (though this information is included in cost data). Public hospitals see patients at “outpatient clinics” after discharge. However, this service is not billed through any of the available datasets and will not be selected. Similarly, private hospitals may bill through MBS so some patient visits may be collected. Furthermore, the response rate of the baseline 45 and Up questionnaire was 19% [17]; therefore, findings may not be generalizable to the entire population in NSW or Australia. Due to the characteristics of the SIDIAP database, which is a primary healthcare database and despite the linkage to hospital data, some information was not available. This information included data from patients’ visits to the ER (not leading to hospitalization) and outpatient specialist visits directly referred by the hospital. This lack of information can be relevant for those fractures that are admitted directly to the ER (without being referred by a primary care physician) and that will not undergo surgery or hospitalization or for those fractures that are treated in a more conservative way and are not hospitalized. Moreover, the cost of a specialist visit after the fracture could not be assessed, either by not having the actual costs of the fracture (we could only retrieve referrals to specialists) or by not having any information on the specialist outpatient visits when referred directly by the hospital. Although the SIDIAP database is representative of the Catalonia population [16], study findings may not be generalizable to the entire population of Spain.

Our approach to identify OF by excluding patients with ICD codes for major trauma may have resulted in misclassification for some of the participants. However, we believe this proportion to be rather small, and therefore, the impact of potential misclassification on the study results is negligible. This approach excludes patients who do not seek medical attention for low-trauma fractures. Differences in unobservable characteristics or differences outside of the study period

(e.g., medical history prior to the start of the study period) might still exist. The presence of a record (EMR, prescribed, or claim) for a prescribed medication does not indicate that the medication was consumed or taken as prescribed. In the US analysis, patients with commercial insurance primarily comprised the study population, and the findings may not be generalizable to the uninsured or those with other insurance, such as Medicare. In contrast to earlier cost evaluations in the literature, our analysis investigated the adjusted HCRU and cost ratios (OF vs. non-OF). As a result, incompatibility caused by differences between countries (such as GDP/healthcare expenditures) may be lessened, and a standardized method of evaluating and comparing economies across countries should be introduced. Even if they are not ideal, we believe that adjusted ratios are a better approach than direct expenses to compare statistics between nations.

Conclusion

The current study demonstrates the substantial economic burden of OF across the five participating countries when compared to non-OF patients. Women with OF use healthcare services at a significantly higher rate. The current study addresses a critical gap in the assessment of the economic burden of osteoporosis research by allowing researchers to assess the relative economic burden of OF across countries using a standardized methodological approach. Strategies directed toward prevention, accurate diagnosis, and intensive treatment of OF are likely to help reduce the economic burden on healthcare systems.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00198-023-06895-4>.

Acknowledgements The authors acknowledge Drs. Kerrin Bleicher and Xenia Dolja-Gore of Sax Institute in Australia, Maciej Rowinski of IGES Institut GmbH in Germany, Drs. Carlen Reyes and Edward Burn of SIDIAP in Spain, and Dr. Siin Kim for data extraction and analysis and Dr. Hector Sanz of IQVIA for his statistical support.

Funding This study was funded by Amgen Inc. and UCB Pharma.

Data availability For Australia, the data that support the findings of this study are collected through the 45 and Up Study (www.saxinstitute.org.au), managed by the Sax Institute in collaboration with major partner Cancer Council NSW and partners the Heart Foundation and the NSW Ministry of Health. Restrictions apply to the availability of these data, which were used under license for this study. For Germany, the data that support the findings of this study are available from IGES Institut GmbH (<https://www.iges.com/>). Restrictions apply to the availability of these data, which were used under license for this study. For South Korea, the data that support the findings of this study are available from the National Health Insurance Service database (<https://nhiss.nhis.or.kr/>), and the results do not necessarily represent the opinion of the National Health Insurance Corporation. Restrictions apply to the availability of these data, which were used under license for this study. For Spain, the data that support the findings of this study are available from SIDIAP (<https://www.sidiap.org/>). Restrictions apply to the

availability of these data, which were used under license for this study. For the USA, the data that support the findings of this study are available from IQVIA (<https://www.iqvia.com/>). Restrictions apply to the availability of these data, which were used under license for this study.

Declarations

Ethics approval The Sax Institute's 45 and Up Study has ethical approval from the University of New South Wales Human Research Ethics Committee. Ethics approval for this project was provided by the NSW Population Health Services Research Ethics Committee (approval 2019/ETH00118). Due to the nature of secondary data, formal consent was not required for the Germany, South Korea, Spain, and US studies.

Informed consent All 45 and Up Study participants provided informed consent for the use of their data in study-approved projects. Informed consent was not applicable to the Germany, South Korea, Spain, and US studies.

Conflict of interest Alireza Moayyeri is an employee of UCB Pharma and holds UCB stocks. Joshua Warden is an employee of UCB Pharma with no UCB stock. Sola Han has no conflict of interest. Hae Sun Suh received a research grant from Amgen Inc. to conduct the South Korean study of this work at Kyung Hee University. Rafael Pinedo-Villanueva has received research funding from the UK NIHR, the International Osteoporosis Foundation, Kyowa Kirin Services, Fondation privée des HUG (Geneva, Switzerland), Amgen Inc., and the Royal Osteoporosis Society and lecture fees and/or consulting honoraria from Amgen Inc., UCB, Kyowa Kirin Services, Astellas, the International Osteoporosis Foundation, and Mereo BioPharma. Nicholas C. Harvey reports personal fees, consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, Amgen Inc., MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, and Internis Pharmaceuticals, outside the submitted work. Jeffrey R. Curtis reports consulting fees and research grants from Amgen Inc. Stuart Silverman received research grants, consulting fees, and honoraria from Amgen Inc., and honoraria from Radius Health. Jasjit K. Multani is an employee of IQVIA, which was contracted by Amgen Inc. and UCB to conduct the Australia, Spain, and US studies of this work. Eric J. Yeh is an employee of Amgen Inc. and holds Amgen stock.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

- Williams SA, Chastek B, Sundquist K, Barrera-Sierra S, Leader DJr, Weiss RJ, Wang Y, Curtis JR (2020) Economic burden of osteoporotic fractures in US managed care enrollees. *Am J Manag Care* 26:e142–e149
- Kaffashian S, Raina P, Oremus M, Pickard L, Adachi J, Papadimitropoulos E, Papaioannou A (2011) The burden of osteoporotic fractures beyond acute care: the Canadian Multicentre Osteoporosis Study (CaMos). *Age Ageing* 40:602–607
- Watts J, Abimanyi-Ochom J, Sanders K (2013) Osteoporosis costing all Australians. A new burden of disease analysis 2012–2022. <https://healthybonesaustralia.org.au/wp-content/uploads/2020/11/Burden-of-Disease-Analysis-2012-2022.pdf>. Accessed 28 September 2022
- Borgström F, Karlsson L, Ortsäter G et al (2020) Fragility fractures in Europe: burden, management and opportunities. *Arch Osteoporos* 15:59
- Kim HY, Ha YC, Kim TY, Cho H, Lee YK, Baek JY, Jang S (2017) Healthcare costs of osteoporotic fracture in Korea: information from the National Health Insurance Claims Database, 2008–2011. *J Bone Metab* 24:125–133
- Persaud A, Bhugra D, Valsraj K, Bhavsar V (2021) Understanding geopolitical determinants of health. *Bull World Health Organ* 99:166–168
- Koopmanschap MA, Touw KC, Rutten FF (2001) Analysis of costs and cost-effectiveness in multinational trials. *Health Policy* 58:175–186
- Burgard SA, Chen PV (2014) Challenges of health measurement in studies of health disparities. *Soc Sci Med* 106:143–150
- Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 17:1726–1733
- The North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. *Menopause* 17:25–54
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. *JAMA* 285:785–795
- Agresti A (2007) Introduction to categorical data analysis, 2nd edn. John Wiley, New Jersey
- Wallace AE, Kaila S, Bayer V, Shaikh A, Shinde MU, Willey VJ, Napier MB, Singer JR (2019 Feb) Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. *J Manag Care Spec Pharm* 25(2):205–217
- Tran O, Silverman S, Xu X, Bonafede M, Fox K, McDermott M, Gandra S (2021) Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women. *Osteoporos Int* 32:1195–1205
- Surís X, Vela E, Clèries M, Pueyo-Sanchez MJ, Llargués E, Larrosa M (2022) Epidemiology of major osteoporotic fractures: a population-based analysis in Catalonia, Spain. *Arch Osteoporos* 17:47
- Pagès-Castellà A, Carbonell-Abella C, Avilés FF, Alzamora M, Baena-Díez JM, Laguna DM, Nogués X, Díez-Pérez A, Prieto-Alhambra D (2012) Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study. *BMC Musculoskelet Disord* 13:79
- Bleicher K, Summerhayes R, Baynes S et al (2023) (2023) Cohort profile update: the 45 and Up Study. *Int J Epidemiol*. 52(1):e92–e101

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.